Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.Melissa Yan, Nasser H. Hanna, Salma K. Jabbour et al.|Journal of Clinical Oncology|2020Cited by 12
Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.Melissa Yan, Nasser H. Hanna, Greg Andrew Durm et al.|Journal of Clinical Oncology|2019Cited by 9